Quarterly report · Q1
2796.TEDINET S100S04W
Period2023-06-01 → 2023-08-31
Filed2023-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.5bn | 2023-06-01 → 2023-08-31 | Cons. | Net sales |
| Revenue | ¥52.0bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.9bn | 2022-06-01 → 2022-08-31 | Cons. | Net sales |
| Operating income | ¥331m | 2023-06-01 → 2023-08-31 | Cons. | Operating income |
| Operating income | ¥348m | 2022-06-01 → 2022-08-31 | Cons. | Operating income |
| Ordinary income | ¥331m | 2023-06-01 → 2023-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥341m | 2022-06-01 → 2022-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥312m | 2023-06-01 → 2023-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥318m | 2022-06-01 → 2022-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥123m | 2023-06-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥333m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥111m | 2022-06-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥127m | 2023-06-01 → 2023-08-31 | Cons. | Profit loss |
| Net income | ¥114m | 2022-06-01 → 2022-08-31 | Cons. | Profit loss |
| Total assets | ¥23.6bn | at 2023-08-31 | Cons. | Assets |
| Total assets | ¥23.4bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥23.2bn | at 2022-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.6bn | at 2023-08-31 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.0bn | at 2023-08-31 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2023-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2023-05-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥13.11 | 2023-06-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.45 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11.88 | 2022-06-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.93 | 2023-06-01 → 2023-08-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.89 | 2022-06-01 → 2023-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥8.99 | 2022-06-01 → 2022-08-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 28.3% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2023-08-31 | ¥185m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2023-08-31 | ¥185m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2023-08-31 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-08-31 | −¥78m |
| jpcrp040300-q1r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q1r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q1r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2023-08-31 | −¥9m |
| jpcrp040300-q1r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2023-08-31 | ¥155m |
| jpcrp040300-q1r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2023-08-31 | ¥155m |
| jpcrp040300-q1r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2023-08-31 | ¥11m |
| jpcrp040300-q1r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2023-08-31 | ¥10.9bn |
| jpcrp040300-q1r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2023-08-31 | ¥10.9bn |
| jpcrp040300-q1r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2023-08-31 | ¥379m |
| jpcrp040300-q1r_E05379-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-08-31 | ¥126m |
| jpcrp040300-q1r_E05379-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-08-31 | ¥126m |
| jpcrp040300-q1r_E05379-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-08-31 | ¥27m |
| —segment total | revenue | 2023-06-01 → 2023-08-31 | ¥13.3bn |
| —segment total | revenue external | 2023-06-01 → 2023-08-31 | ¥13.3bn |
| —segment total | segment profit | 2023-06-01 → 2023-08-31 | ¥408m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-08-31 | ¥13.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-08-31 | ¥13.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-08-31 | ¥409m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-06-01 → 2022-08-31 | ¥204m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-06-01 → 2022-08-31 | ¥204m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-06-01 → 2022-08-31 | ¥21m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-08-31 | −¥75m |
| jpcrp040300-q1r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2022-06-01 → 2022-08-31 | ¥2.0bn |
| jpcrp040300-q1r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2022-06-01 → 2022-08-31 | ¥2.0bn |
| jpcrp040300-q1r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2022-06-01 → 2022-08-31 | −¥35m |
| jpcrp040300-q1r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2022-06-01 → 2022-08-31 | ¥169m |
| jpcrp040300-q1r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2022-06-01 → 2022-08-31 | ¥169m |
| jpcrp040300-q1r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2022-06-01 → 2022-08-31 | ¥20m |
| jpcrp040300-q1r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2022-06-01 → 2022-08-31 | ¥10.4bn |
| jpcrp040300-q1r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2022-06-01 → 2022-08-31 | ¥10.4bn |
| jpcrp040300-q1r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2022-06-01 → 2022-08-31 | ¥398m |
| jpcrp040300-q1r_E05379-000Medical Mallreportable segment | revenue | 2022-06-01 → 2022-08-31 | ¥126m |
| jpcrp040300-q1r_E05379-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2022-08-31 | ¥126m |
| jpcrp040300-q1r_E05379-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2022-08-31 | ¥19m |
| —segment total | revenue | 2022-06-01 → 2022-08-31 | ¥12.7bn |
| —segment total | revenue external | 2022-06-01 → 2022-08-31 | ¥12.7bn |
| —segment total | segment profit | 2022-06-01 → 2022-08-31 | ¥402m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-08-31 | ¥12.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-08-31 | ¥12.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-08-31 | ¥424m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 375
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)自己保有株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式単元株式数100株 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)同上 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ファーマライズホールディングス㈱ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都中野区中央１-38-１ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |